News & Updates

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

A few patients in the intensive care unit (ICU) have registered a fever >38.5 °C while on dexmedetomidine therapy, reports a recent study.

A nonrestrictive fluoroquinolone reduction initiative at an urban teaching hospital has substantially lessened the use of this drug, which is associated with decreased antibiotic resistance in Staphylococcus aureus and Pseudomonas aeruginosa, a study has shown.

The use of fluocinolone acetonide improves visual outcomes and disease control in patients with diabetic macular edema (DME), as measured by a significant reduction in annual treatment burden, according to a study.